Initiation of antipsychotics was nearly 3 times more common in patients with Parkinson disease vs controls, with the incidence rate found to increase approximately 4 years prior to PD diagnosis.
Initiation of antipsychotics was shown to be significantly higher among patients with Parkinson disease (PD) before and after diagnosis, according to study findings published in Parkinsonism & Related Disorders.
Nearly half of people with PD report psychotic symptoms, including hallucinations, delusions, and false sense of presence, noted researchers, with use of antipsychotics common among these patients. Notably, these symptoms may occur prior to the initiation of motor fluctuations during the prodromal stage, but the underlying cause of this, as well as PD-related psychosis, remains poorly understood.
“There is, as far as we know, no previous studies about the incidence of antipsychotic use before PD diagnosis. This information has clinical relevance in relation to understanding the burden of psychotic symptoms already in the prodromal stage,” said the study authors.
Leveraging data from the nationwide register-based FINPARK-study, which included 20,994 community-dwelling patients with PD at the time of diagnosis who received special reimbursement for PD drugs between 1996 and 2015 in Finland, they sought to compare the incidence of antipsychotic use among people with and without PD from 10 years before to 10 years after the diagnosis.
“For those diagnosed before or during the year 2005, we used year 1995 as a 1-year washout period. We excluded persons who had bought antipsychotics during the washout period or those who were hospitalized for over 50% of the washout period or hospitalized for the last 90 days of the washout period,” explained researchers.
A total of 20,994 people with PD and 142,944 people without were included in the analysis, with the study cohort evaluated on the rate of antipsychotic initiations (initiation rate [IR]) per 1000 person-years for every 6 months beginning from 10 years before to 10 years after the diagnosis or index date (date of PD diagnosis).
Overall, 26.9% (n = 5654) of people with PD initiated antipsychotics vs 9.7% (n = 13,887) of people without PD during the entire follow-up (IR, 20.3 and 6.3 per 1000 person-years for persons with and without PD, respectively; IR ratio [IRR], 3.20; 95% CI, 3.10-3.30).
The initiation rates were shown to be higher in patients with PD before (IR, 6.5 and 3.0 per 1000 person-years; IRR, 2.18; 95% CI, 2.03-2.33) and after the index date (IR, 43.3 and 11.7 per 1000 person-years; IRR, 3.70; 95% CI, 3.57–3.83). Moreover, the incidence rate was found to increase in people with PD approximately 4 years prior to PD diagnosis.
Most commonly initiated antipsychotics were quetiapine (n = 3642; 64.4%) in people with PD and risperidone (n = 5232; 37.7%) in controls.
The researchers concluded that psychotic symptoms may be challenging to recognize as prodromal symptoms of PD since they can occur years before motor symptoms and “thus, cannot be clinically associated with the diagnosis of PD.”
Reference
Lilja S, Tolppanen AM, Koponen M, Hartikainen S, Tiihonen M. Incidence of antipsychotic use among community dwellers with and without Parkinson’s disease. Parkinsonism Relat Disord. 2022 Aug 24;103:69-72. doi:10.1016/j.parkreldis.2022.08.024
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More